Amolyt Pharma was a clinical-stage biopharmaceutical company based in Lyon, France. The company had pipeline of potential best-in-class treatments for metabolic disorders. Its lead compound was precisely designed agonist against parathyroid receptor for the treatment of hypoparathyroidism. In 2024, Amolyt Pharma was acquired by AstraZeneca for $1.05B USD.
Hypoparathyroidism
CTI LSF III
Syndicate
n/a
January 21, 2023
Amolyt Pharma acquired by Alexion for $1.05B USD
Series C
Amolyt’s parathyroid receptor agonist is specifically designed to bind to the calcium channel in the kidney and not in the bone, thus restoring serum calcium level without affecting deteriorating bone
